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A method of indicating the presence of a bacterial infection 
in a biological sample is provided . The method detects a 
marker for infection by providing a device , the device 
including a biosensor , an interaction arising between the 
biosensor and the marker when the marker is present in the 
biological sample . Contacting at least a part of the biological 
sample with the biosensor of the device , therefore , provides 
analysis of the biological sample with respect to the marker 
by detecting for the interaction between the biosensor and 
the marker . A preferred marker is the enzyme amylase . 
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METHOD OF DETECTING BACTERIAL 
INFECTION IN A BIOLOGICAL SAMPLE 
[ 0001 ] This invention concerns improvements in and 
relating to detection , particularly of the presence of a disease 
and / or of infection at a site , and / or improvements in and 
relating to transportation , particularly the transportation of 
pharmaceutical compounds to a site of disease and / or infec 
tion . 
10002 ] There are many situations where detection of infec 
tion is a significant issue . In some circumstances , the pri 
mary injury to the human body ( for example a burn injury ) 
itself causes symptoms that mimic infection . The practice of 
microbiological swabbing , and subsequent identification of 
organisms confirms their presence in a wound , but not the 
presence of infection . Multi - drug resistance is a clinical 
concern , and administering antibiotics where there might be 
no clinical need increases costs , and increases the well 
known risks from over use of antibiotics . 
10003 ] EP0145398 provides one form of sensor for the 
detection of amylase activity for the purpose of revealing a 
disease which causes enhanced levels of amylase . There is 
no suggestion that amylase ( or closely related species ) is 
indicative of infection and so no suggestion that the detec 
tion of amylase provides for the detection of infection . The 
approach is limited merely to the revealing of one or a 
limited number of specific diseases . 
[ 0004 GB2426335 relates to the detection of wound 
infection , but through the detection of reactive oxygen 
species . These are unrelated to amylase and so there no 
suggestion that amylase is indicative of infection and so no 
suggestion that the detection of amylase provides for the 
detection of infection . 
[ 0005 ] US2012 / 0309036 , W097 / 29366 , US2015 / 
0004627 and WO2010 / 124270 all provide different types of 
sensors . None is for the detection of amylase and none 
provides that amylase is indicative of infection and so no 
suggestion that the detection of amylase provides for the 
detection of infection exists . 
[ 0006 ] Approaches that do detect for bacterial infection , 
through very different mechanisms to the present invention , 
often determine the presence of bacteria and not whether the 
bacteria are causing infection . The present invention has 
amongst its potential aims to provide an improved method of 
analysis for a biomarker indicative of infection , particularly 
bacterial infection . The present invention has amongst its 
potential aims to provide an improved method for detection 
of infection , particularly bacterial infection . The present 
invention has amongst its potential aims an improved 
method for indicating the presence of infection to cause 
further investigations and / or further evaluation before mak 
ing a clinical diagnosis and / or proposing a treatment . The 
present invention has amongst its potential aims to provide 
an improved method of analysis for a biomarker indicative 
of infection , particularly bacterial infection . 
[ 0007 ] The present invention has amongst its potential 
aims to provide an improved composition for pharmaceuti 
cal use . The present invention has amongst its potential aims 
to provide an improved composition for the targeted deliv 
ery of a composition for pharmaceutical use . 
0008 ] . According to a first aspect the invention provides a 
method of analysing a biological sample for a marker , the 
method comprising : 
[ 0009 ] providing a device , the device including a sensor 
for the marker ; 
[ 0010 ] contacting at least a part of the biological sample 
with the device ; 
[ 0011 ] analysing the at least a part of the biological sample 
with respect to the marker ; 
[ 0012 ] indicating a characteristic of the marker using the 
device ; 
[ 0013 ] wherein the biomarker is an enzyme , preferably 
amylase . 
[ 0014 ] The first aspect of the invention may further 
include that : 
[ 0015 ] the method of analysing is a method of indicat 
ing the presence of infection in the biological sample ; 
and / or 
[ 0016 ] the method may include the sensor being a 
biosensor ; and / or 
[ 0017 ] the method may include an interaction arising 
between the sensor and the marker when the marker is 
present in the biological sample ; and / or 
[ 0018 ] the method may further include contacting the at 
least a part of the biological sample with the biosensor 
of the device ; and / or 
[ 0019 ] the method may further include detecting for the 
interaction between the biosensor and the marker ; 
[ 0020 ] the method may further include the characteris 
tic being the presence or absence of the marker . 
( 0021 ] According to a second aspect the invention pro 
vides a method of indicating the presence of infection in a 
biological sample by investigating a marker for infection , 
the method comprising : 
[ 0022 ] providing a device , the device including a biosen 
sor , an interaction arising between the biosensor and the 
marker when the marker is present in the biological sample ; 
[ 0023 ] contacting at least a part of the biological sample 
with the biosensor of the device ; 
[ 0024 ] analysing the at least a part of the biological sample 
with respect to the marker by detecting for the interaction 
between the biosensor and the marker ; 
[ 0025 ] indicating a characteristic of the marker using the 
device , the characteristic being the presence or absence of 
the marker ; 
[ 00261 wherein the marker is an enzyme , preferably amy 
lase . 
[ 0027 ] The first and second aspects of the invention may 
include any of the following features , options or possibili 
ties . 
[ 0028 ] . The method of analysing may be a method of 
diagnosis for infection . 
[ 0029 ] The method of analysing may be a method of 
analysing for and / or detecting for and / or diagnosing 
elevated marker levels at a site , for instance elevated levels 
compared with an experimentally obtained baseline . The 
method of analysing may be a method of analysing for 
and / or detecting for and / or diagnosing elevated marker 
levels at a site , for instance elevated levels compared with an 
experimentally obtained baseline , arising from infection at a 
site . The method of analysing may be a method of analysing 
for and / or detecting for and / or diagnosing elevated marker 
levels at a site , for instance elevated levels compared with 
marker levels at another location of the same patient , such 
as the blood . The method of analysing may be a method of 
analysing for and / or detecting for and / or diagnosing 
elevated marker levels at a site , for instance elevated levels 
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tior 
compared with marker levels at another location of the same 
patient , such as the blood , the elevated level arising from 
infection at a site . 
[ 0030 ] The method of analysing may be a method of 
quantifying the amount of the marker in the at least a part of 
the biological sample . The method may quantify the activity 
of the marker . The method may quantify the concentration of 
the marker . The method may quantify the activity of the 
marker relative to the activity of the marker in a reference 
sample . The method may quantify the concentration of the 
marker relative to the concentration of the marker in at least 
a part of a reference sample . 
10031 ] The reference sample may be another biological 
sample taken from the same source , for instance the same 
human or animal . The reference sample is preferable taken 
from another site on the source to the site being analysed , for 
instance for infection . The other site may be a vein . The 
reference same may be a biological sample in which the 
presence or amount of the marker is not influenced by the 
presence of infection at the site being analysed . The refer 
ence sample may be an intravascular fluid , such as whole 
blood or any of the separated components of blood , for 
example serum or plasma . One or more of the separated 
components may be considered . 
[ 0032 ] The biological sample may be body fluids and / or 
cells and / or processed cells and / or a tissue sample taken 
from the site to be analysed . The biological sample may be 
extracted from an item which has been in proximity with the 
site to be analysed , such as a dressing , pad , compress , swab , 
skin substitutes , biomembrane . The biological sample may 
be taken from inside and / or outside the body . 
[ 0033 ] The site may by on the exterior of a body and / or the 
site may be interior to a body . The site may be a surgical site , 
including a plastic surgery site . The site may be a disease site 
and / or a pathology site . The site may be an infection site . 
The site may be an injury site . The site may be a wound , for 
instance an open wound such as a tear , cut , puncture , 
incision , laceration , abrasion , avulsion , penetration or gun 
shot wound or for instance a closed wound such as a 
contusion , hematoma or crush injury . The site may particu 
larly be a burn . The site may be superficial or it may be deep , 
and in any layer , tissue , organ or bodily fluid . 
[ 0034 ] The infection may be a bacterial infection . A bac 
terial infection may be defined as a proliferation of bacteria 
on or inside a human or animal which causes harm to the 
human or animal . The bacterial infection may be homoge 
neous or heterogeneous . The bacterial infection may be 
localised to one or more sites or systemic . The bacterial 
infection may be symptomatic or asymptomatic . 
[ 0035 ] Preferably the method is distinguishing for bacte 
rial infection . 
[ 0036 ] Preferably the method is distinguishing between 
bacterial infection and inflammation . 
[ 0037 ] The method may provide sensitivity to bacterial 
infection . The sensitivity may be greater than 80 % , prefer 
ably greater than 85 % , more preferably greater than 90 % 
and ideally 98 % or more . 
[ 0038 ] The method may provide specificity with respect to 
the absence of bacterial infection . The specificity may be 
greater than 75 % , preferably greater than 80 % , more pref 
erably greater than 85 % and ideally 90 % or more . 
[ 0039 ] The infection may be caused by Gram positive 
( such as Staphylococcus spp . ) and / or Gram negative organ - 
isms ( such as Acinetobacter spp . ) . The infection may be 
caused aerobic and / or micro - aerobic organisms ( such as 
Streptococcus sp . ) and / or anaerobic organisms ( such as 
Clostridium spp . ) . The infection may be mono - microbial or 
poly - microbial . The infection may be a poly - microbail 
infection which is synergistic or non - synergistic . The infec 
tion may be one or more of : Steptococci , such as Strepto 
coccus pyrogenesi , and / or Enterococci , such as Enterococ 
cus faecalis , and / or Staphylococci , such as Staphylococcus 
aureus , and / or Pseudomonas , such as Pseudomonas aerugi 
nosa , Enterobacter , Escherichia coli , Klebsiella , Bacillus , 
such as B . cerus , Clostridium , such as C . perfringens , C . 
teanii , C . difficile , Proteus , Bacteroides , Clostridium . 
[ 0040 ] The marker is preferably an enzyme which is a 
catalyst for the hydrolysis of starch into sugars . The marker 
may be a glycoside hydrolase . The marker is most preferably 
amylase . The marker may be one or more or all of a mixture 
of enzymes . The marker is preferably produced by the 
human or animal from which the biological sample is 
obtained . The marker is preferably an enzyme which is a 
catalyst for the hydrolysis of starch into sugars produced by 
the human or animal from which the biological sample is 
obtained . The marker may be a glycoside hydrolase prefer 
ably produced by the human or animal from which the 
biological sample is obtained . The marker is most preferably 
amylase preferably produced by the human or animal from 
which the biological sample is obtained . The marker may be 
one or more or all of a mixture of enzymes preferably 
produced by the human or animal from which the biological 
sample is obtained . 
[ 0041 ] The device may have a separate existence outside 
of the limitations of the method and purpose of the method . 
[ 0042 ] The device may include the sensor together with 
one or more or all of , a power source , control electronics , a 
computer processor , computer memory , a user interface , a 
user viewable display , a signal output connection , a signal 
input connection . 
[ 0043 ] The device is preferably a self - contained unit . The 
device is preferably portable . The device may be hand - held 
and / or desk - top . 
[ 0044 ] The sensor may be screen printed on to a part of the 
device and / or a sensor support . The sensor may detect the 
marker without the use of labels for the marker . The sensor 
may be an immunosensor . The sensor is preferably a gra 
phene based sensor . 
[ 0045 ] The sensor may include an aromatic amine , such as 
aniline , on a support . The support may be a graphene 
support , gold support , zinc oxide support , iron oxide support 
or other forms of carbon support . Electropolymerisation of 
the aromatic amine , such as aniline , onto the sensor support 
is preferred , for instance to achieve increased sensitivity 
and / or lower limits of quantification . The sensor may be 
constructed by in situ electropolymerization of the aromatic 
amine , such as aniline , onto a graphene support . 
[ 0046 ] The sensor may include an enzyme antibody , pref 
erably an enzyme specific antibody . The sensor may include 
a glycoside hydrolase antibody , preferably a glycoside 
hydrolase specific antibody . The sensor may include an 
amylase antibody , preferably an amylase specific antibody . 
Preferably the sensor includes an a - amylase antibody , most 
preferably an a - amylase specific antibody . 
[ 0047 ] The sensor may be constructed by covalently bind 
ing the enzyme specific antibody to a layer . The layer may 
be a transducer layer . The layer may be a conductive 
polymer layer , such as a polyaniline layer . 
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[ 0048 ] The transducer layer may be separate from a con 
trol electronics layer , may be integrated there with or may be 
the same layer . The control electronics layer may be a 
controlling device assembly . 
[ 0049 ] The control electronics , such as a controlling 
device assembly , may use electrochemical impedance spec 
troscopy to analyse for and / or detect for and / or indicate the 
marker . The control electronics , such as a controlling device 
assembly , may use variation in the dielectric properties of 
the at least a part of the sample and / or the sensor as a 
function of frequency . 
[ 0050 ] The detecting for the interaction may use electro 
chemical impedance spectroscopy . The detection for the 
interaction may use variation in the dielectric properties of 
the at least a part of the sample and / or the sensor as a 
function of frequency . The sensor differs from previous 
electrochemical impedance spectroscopy based sensors by 
using electropolymerization in the construction of the sensor 
and / or in terms of the sensor being used to determine the 
presence of bacterial infection through the detection of 
amylase . 
[ 0051 ] Preferably the electrochemical impedance spec 
troscopy has a linear response against a - amylase concen 
tration . A linear response may be considered to be a response 
which deviates no more than 10 % from linear . 
[ 0052 ] Preferably electrochemical impedance spectros 
copy generates a signal output when the marker is present in 
the at least part of the sample . Preferably the signal output 
varies with activity of the marker and / or concentration of the 
marker , ideally in a linear response . 
10053 ] The sensor may detect concentrations of the 
marker , preferably in a simulated biological sample , bio 
logical sample or human plasma , as low as 100 International 
Units / LºU / L ) , preferably as low as 50 International Units / L 
( IU / L ) , more preferably as low as 10 International Units / L 
( IU / L ) , and ideally as low as International Units / L ( IU / L ) . 
The sensor may have a limit of detection as low as 1 U / L , 
preferably as low as 0 . 4 U / L , more preferably as low as 0 . 1 
U / L and ideally as low as 0 . 025 U / L and possibly even as 
low as 0 . 01 U / L . 
[ 0054 ] The sensor may display a linear response to 
increasing a - amylase concentration between 1 and 1000 
International Units / L ( IU / L ) , and / or a limit of detection of 
0 . 025 U / L and possibly even as low as 0 . 01 U / L . 
[ 0055 ] The contacting of the at least a part of the sample 
with the sensor may be provided by placing the sample on 
the sensor and / or dipping the sensor in the sample and / or 
inserting the sample into the device . 
[ 0056 ] The characteristic may be the presence of the 
marker . The characteristic may be the absence of the marker . 
The characteristic may be the level of the marker , for 
instance absolutely and / or relative to one or more predeter 
mined thresholds . The characteristic may be the quantity of 
the marker . The quantity of the marker may be the activity 
of the marker and / or the concentration of the marker . 
100571 . The characteristic may be the level of the marker in 
a sample taken from one type of site compared with the level 
of the marker in a sample taken from another type of site . 
The characteristic may be the difference between the level of 
the marker in a sample taken from one type of site compared 
with the level of the marker in a sample taken from another 
type of site . The characteristic may be the quotient of the 
level of the marker in a sample taken from one type of site 
to the level of the marker in a sample taken from another 
type of site and / or vice versa . 
[ 0058 ] The characteristic may be expressed in terms of 
activity and / or concentration of the marker . 
[ 0059 ] The one type of site may be the infection site or 
potential infection site . The another type of site may be a site 
distal from the one type of site in the same patient . The 
another type of site may be a blood or plasma source . The 
another type of site may be associated with the same patient 
as the one type of site , but the another type of site may be 
from a control or reference individual or group of individu 
als . 
10060 ] The characteristic may be outputted from the 
device . The output may be a visual display to the user . The 
output may be an electronic signal and / or electrochemical 
signal . The output may be a permanent recording of the 
characteristic . 
[ 0061 ] The method of analysis may include a method for 
detecting the presence of infection . The method of analysing 
may include a method of detecting the type of infection . The 
type of infection may be with respect to a classification of 
the source of infection , for instance Gram negative or Gram 
positive . The type of infection may be with respect to the 
classification of the source of the infection , for instance 
bacterial , most preferably bacterial only , with possibilities 
for viral , fungal , protazoal . The type of infection may be 
with respect to the characterisation of the genus of the source 
of the infection , for instance one or more selected from the 
group : Steptococci , Enterococci , Staphylococci , Pseudomo 
nas , Enterobacter , Klebsiella , Bacillus , Clostridium . The 
type of infection may be with respect to the characterisation 
of the species of the source of the infection , for instance one 
or more selected from the group : Streptococcus pyrogenesi , 
Enterococcus faecalis , Staphylococcus aureus , Pseudomo 
nas aeruginosa , Escherichia coli , Bacillus cerus , 
Clostridium perfringens , Clostridium teanii , Clostridium 
difficile . 
[ 0062 ] The method may be a method of verifying that the 
marker is present at a site , such that the marker can activate 
a pharmaceutical compound when the pharmaceutical com 
pound is present at the site . The method may include a 
method of predicting and / or estimating the activation rate of 
a pharmaceutical compound at a site by the marker . This is 
a useful addition to situations in which an inactive form may 
convert to the active form because the marker , for instance 
amylase , causes the active compound to be rendered phar 
maceutically active , for instance by causing breakdown of 
the inactive form . 
[ 0063 ] The method may be a method of investigating a site 
to establish that the marker is preferentially present at the 
site , such that transportation of a pharmaceutical compound 
as part of a combination with the marker , such as amylase , 
to the site occurs . 
[ 0064 ] According to a third aspect the invention provides 
a composition comprising a pharmaceutical compound com 
bined with a carrier constituent , the carrier constituent 
comprising amylase . 
[ 0065 ] According to a fourth aspect the invention provides 
a composition comprising a pharmaceutical compound com 
bined with a carrier constituent , the carrier constituent 
comprising an enzyme . 
[ 0066 ] The enzyme is preferably a catalyst for the hydro 
lysis of starch into sugars . The enzyme may be a glycoside 
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hydrolase . Most preferably the enzyme is amylase . A mix 
ture of enzymes may be provided . 
[ 0067 ] According to a fifth aspect of the invention there is 
provided a method of treatment comprising administering to 
a human or animal of a composition comprising a pharma 
ceutical compound combined with a carrier constituent , the 
carrier constituent comprising amylase . 
[ 0068 ] The method of treatment may be a method of 
treating infection and / or preventing infection . The method 
of treatment may be for a human or animal with burns . 
100691 . The third and / or fourth and / or fifth aspects of the 
invention may include any of the following features , options 
and possibilities . 
[ 0070 ] The pharmaceutical compound may be a pharma 
ceutically active compound . The pharmaceutical compound 
may be pharmaceutically active compound whilst combined 
with the carrier constituent . The pharmaceutical compound 
may be pharmaceutically active compound after being sepa 
rated from the carrier constituent . The pharmaceutical com 
pound may be a pharmaceutically in - active compound . The 
pharmaceutical compound may transition from being a 
pharmaceutically in - active compound to a pharmaceutically 
active compound due to an event . The event may be the 
passage of time and / or becoming separated from the carrier 
constituent and / or interaction with another compound . 
[ 0071 ] The pharmaceutical compound may be combined 
reversibly . The pharmaceutical compound may be combined 
irreversibly . 
[ 0072 ] The pharmaceutical compound may be combined 
with the carrier constituent , by being combined directly with 
the amylase . The pharmaceutical compound may be com 
bined directly with the amylase by linking the pharmaceu 
tical compound with the amylase . The linking may be 
covalent linking . The linking may be cross - linking . The 
linking may be covalent binding . The linking maybe ionic 
binding . 
[ 0073 ] The pharmaceutical compound may be combined 
with the carrier constituent , by being combined directly with 
an intermediary . The combination of the pharmaceutical 
compound with the intermediate may be irreversible or 
reversible . The intermediary may be combined directly with 
the amylase . The pharmaceutical compound may be com 
bined directly with the intermediary and / or the intermediary 
may be combined directly with the amylase by linking . The 
linking may be the same or different with respect to the two 
links . The linking may be covalent linking . The linking may 
be cross - linking . The linking may be covalent binding . The 
linking maybe ionic binding . 
10074 ] The combination of the pharmaceutical compound 
with the carrier constituent may be irreversible or reversible . 
The pharmaceutical compound can preferably be released 
from the combination with the carrier constituent . The 
pharmaceutical compound may be inactive or the activity 
may be impaired or inhibited when in combination with the 
carrier constituent . Preferably the pharmaceutical compound 
is not impaired or inhibited in its activity when released from 
the combination with the carrier constituent and / or when the 
linking is reversed . 
[ 0075 ] The intermediary may be a cross - linking com 
pound . The pharmaceutical compound may be bound 
directly to amylase . This can be provided by a variety of 
mechanisms including but not only , zero - length cross link 
ing . The pharmaceutical compound may be bound to an 
intermediary which is then itself bound to amylase . The 
intermediary may be non - biodegradable , for example poly 
( ethylene ) glycol , or may be biodegradable . 
[ 0076 ] The pharmaceutical compound may treat or pre 
vent infection , particularly bacterial infection . The pharma 
ceutical compound may treat or prevent infection by , 
amongst others , Steptococci , such as Streptococcus pyro 
genesi , and / or Enterococci , such as Enterococcus faecalis , 
and / or Staphylococci , such as Staphylococcus aureus , and / 
or Pseudomonas , such as Pseudomonas aeruginosa , Entero 
bacter , Escherichia coli , Klebsiella , Bacillus , such as B . 
cerus , Clostridium , such as C . perfringens , C . teanii , C . 
difficile , Proteus , Bacteroides , Clostridium . 
[ 0077 ] The pharmaceutical compound may one or more 
of , including combinations of : antibiotics , analgesics , opi 
oids , anti - inflammatories , antihistamines . 
[ 0078 ] The pharmaceutical compound may be used to 
deliver therapy in multiple modalities , alone or in combi 
nation . 
[ 0079 ] The pharmaceutical compounds may include tar 
geted pharmacotherapy and / or targeted radiologically active 
compounds and / or compounds activated by light , chro 
mophores , and / or compounds activated by sound , such as 
ultrasound . The pharmaceutical compound may include 
compounds acting through emission or through their 
response to emissions , as opposed to just a pharmaceutical 
chemical interaction . 
[ 0080 ] One or more different pharmaceutical compounds 
may be provided in the composition . 
[ 0081 ] The composition may be a parenteral administered 
composition , for instance for injection , including sub - cuta 
neous , intramuscular , intravenous , intra - arterial , intrathecal , 
intra - peritoneal injection . The composition may be an 
enteral administered composition , for instance for oral 
administration . The composition may be provided in a 
medicinal product . 
[ 0082 ] The medicinal product is preferably altered in the 
patient to present the composition in an absorbable form . For 
instance , the medicinal product may disintegrate during 
ingestion and / or in the stomach and / or in the intestine to 
present the composition in an absorbable form . The com 
position in the absorbable form preferably still comprises the 
pharmaceutical compound combined with a carrier constitu 
ent , the carrier constituent comprising amylase . 
[ 0083 ] The composition in the absorbable form , preferably 
still comprising the pharmaceutical compound combined 
with a carrier constituent , the carrier constituent comprising 
amylase , preferably remains in the combined form for a time 
period which provides for a proportion of the combined 
form to be transported to the site to be treated . The propor 
tion of the composition which remains in the combined form 
may be at least 25 % of the total composition after the time 
period . The proportion is more preferably greater than 40 % , 
for instance greater than 50 % of even greater than 70 % . The 
time period may be defined as the time of the peak concen 
tration point at the site being treated . The time period may 
be defined as at least 2 hours after administration . 
[ 0084 ] Particularly when administered orally , the compo 
sition in the combined form is provided with protection from 
being broken down by amylase and / or other intestinal 
enzymes and conditions . The protection may be provided by 
providing linking which is not susceptible to being broken 
by amylase and / or other intestinal enzymes and conditions . 
( 0085 ] The composition , particularly as a medicinal prod 
uct , may be provided in one of the following forms : tablets , 
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[ 0104 ] FIG . 12 is a schematic a illustration of the con 
struction of the graphene sensor , including the electropoly 
merization of polyaniline to the graphene surface . 
AMYLASE 
capsules , powders , granules , microspheres or ointments , 
creams , foams , solutions , suppositories , injections , lotions 
and aerosols . 
[ 0086 ] The composition , particularly as a medicinal prod 
uct , may be provided with one or more excipients , diluents 
or adjuvants . For instance , one or more fillers , glidants , 
binders , lubricants , anti - adherents , disintegrants , buffering 
agents , moisturising agents , preservatives , solvents , solu 
bilising agents , stabilizers . 
[ 0087 ] Various embodiments of the invention will now be 
described , by way of example only and with reference to the 
accompanying drawings in which : 
[ 0088 ] FIG . 1 shows a distribution graph illustrating that 
detection according to the invention was useful across 
different types of bacteria , different types of wound , wound 
dressing , antibiotics , wound site , and depth ; 
[ 0089 ] FIG . 2 illustrates experimental results showing the 
amylase activity for a series of samples , the samples being 
characterised into the group type " plasma ” or the group type 
“ infected fluid ” ; 
[ 0090 ] FIG . 3A illustrates the difference in results for the 
two groups of FIG . 2 using the Mann Whitney matched pairs 
signed test ( P = 0 . 002 ) ; 
[ 0091 ] FIG . 3B illustrates the minor differences in results 
for the groups wound sourced sample and blood sourced 
sample ; 
[ 0092 ] FIG . 3C illustrates the differences in results 
between the “ infected fluid ” group of FIG . 2 and a series of 
control samples ; 
[ 0093 ] FIG . 4 shows a Western blot analysis of amylase 
size distribution showing degradation / cleavage within an 
infected environment ; 
[ 0094 ] FIG . 5 illustrates experimental results showing the 
concentration difference between infected wound fluid and 
plasma for the same individual patient across a series of 
patients ; 
[ 0095 ] FIG . 6 illustrates the concentration difference in the 
results for the two groups using the Mann Whitney matched 
pairs signed test ( P < 0 . 0001 ) ; 
[ 0096 ] FIG . 7a illustrates the concentration difference 
( wound / plasma ) for infected cases , showing a highly sig 
nificant difference ; 
[ 00971 FIG . 7b illustrates the concentration difference 
( wound / plasma ) for non - infected cases , showing no signifi 
cant difference ; 
10098 ] FIG . 7c illustrates the concentration difference 
between experimental cases and controls , showing a highly 
significant difference ; 
[ 0099 ] FIG . 8A provides a Nyquist plot showing the 
effective response of an immunosensor , suitable for use in 
the present invention , to increasing amylase concentrations ; 
[ 0100 ] FIG . 8B shows the resulting EIS calibration curve 
for the immunosensor of FIG . 6A to increasing amylase 
concentrations ; 
[ 0101 ] FIG . 9 provides an EIS calibration curve for the 
immunosensor of FIG . 6A to increasing concentrations of 
amylase in mouse plasma ; 
[ 0102 ] FIG . 10 provides a Nyquist plot showing the 
dynamic range detectable when the sensor was exposed to 
various human plasma concentrations ( 9 . 9 - 1009 . 9 U / L ) ; 
[ 0103 ] FIG . 11 is a Roche Cobas test or recovery , illus 
trating linearity of recovery for amylase in plasma and PBS 
but not linear recovery in infected wound fluid ; and 
[ 0105 ] Amylase is a naturally produced enzyme which 
provides for the breakdown of components in foodstuffs 
consumed by humans , other animals , together with some 
plants and bacteria . The enzyme acts by catalysing the 
hydrolysis of the starches present into sugars . Other 
enzymes then convert those components to glucose to pro 
vide an energy source . 
[ 0106 ] The amylase may be generated by salivary , mam 
mary and lacrimal glands and , in the case of a particular 
isoform in the pancreas . It occurs naturally in humans , 
animals , plants , fungi and bacteria . More properly this is 
a - amylase . A - amylase is also known as 1 , 4 - C - D - glucan 
glucanohydrolase or glycogenase . 
[ 0107 ] In contrast , B - amylase is naturally produced by 
bacteria , fungi and plant seeds and so may be present in 
consumed foodstuffs . B - amylase is also known as 1 , 4 - a - D 
glucan maltohydrolase . y - amylase is primarily found in 
yeast and fungi , but is also naturally produced in some 
human tissues , particularly within the intestine . y - amylase is 
also known as 1 , 4 - a - D - glucan glucohydrolase . 
[ 0108 ] Amylase is known to be an aid to diagnosis , for 
instance through test blood serum , urine or peritoneal fluid 
for hyperamylasemia with a view to informing on acute 
inflammation of the pancreas . 
[ 0109 ] More recently , amylase , particularly a - amylase , 
has been used clinically in pancreatic enzyme replacement 
therapy and other treatments . 
Detection and Quantification of Amylase 
[ 0110 ] A variety of sensors or other forms of assay are 
known which can detect amylase in samples , however , they 
function by detecting the activity of amylase . They do not 
operate through the detection of concentration , are not 
capable of the detection of the concentration levels of 
amylase typically encountered in medical situations and 
samples and do not have the necessary sensitivity to detect 
very low concentration levels of amylase in samples . Fur 
thermore , their response is non - linear in some body fluids , 
with variation in response to the same activity between body 
fluids . A sensor offering this combination of features is not 
available in the prior art . 
[ 0111 ] Activity based detection can be negatively affected 
by deviation on pH away from the 6 . 7 to 7 . 0 range optimal 
for activity and / or due to temperature and / or due to ionic 
composition and / or due to the composition of the fluid 
and / or due to reactions , such as chelation , reducing activity . 
[ 0112 ] In later sections , a sensor is described which allows 
for the accurate detection of low concentrations of amylase 
in samples . 
[ 0113 ] Initially , however , a use of such a sensor will be 
described . The use is in the detection of amylase , more 
specifically the determination of the concentration of amy 
lase , present in a sample so as to inform on the presence of 
infection at a site associated with the source of the sample . 
This is a new pattern of amylase distribution , as compared 
with the four known patterns ; pancreatic , salivary , mac 
roamylasemia and combinations of those three . 
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[ 0114 ] The applicant has established that this new pattern 
of amylase distribution is valid and applicable through the 
following testing . 
[ 0115 ] A library of infections was compiled to represent a 
variety of patient sex , infection locations , bacteria identities , 
dressing type and diagnosis . In the illustrated example of 
FIG . 1 , this was formed of the information from 20 patients . 
The spread of factors was used to investigate whether the 
new pattern was applicable to a wide variety of different 
infections , in terms of organism , site , open and closed 
wounds , superficial and deep infections and the like . 
[ 0116 ] Samples were collected from infection sites and 
tested using a sensor described further below . Samples were 
also collected from plasma simultaneously off each patient 
and tested in the same manner and using the same sensor . 
Plasma amylase was used as the comparator . Whilst amylase 
is present in plasma , the levels are regulated . Infection 
causes enhanced vascular permeability , therefore , large mol 
ecules such as amylase are likely to sequester to the site and 
not be able to drain away because of distorted lymphatics . 
Amylase is also likely to be secreted by some bacteria . 
[ 0117 ] FIG . 2 shows the amylase activity detected for each 
of the samples collected . Some samples were of insufficient 
volume for testing and are shown as absent data points . 
Testing was possible for 14 samples . FIG . 2 shows whether 
these were sample associated with an infection site or 
plasma . The site being infected was established to be true 
through alternative testing approaches . 
[ 0118 ] Amylase is normally present in human plasma . A 
substantial difference between the plasma and the infected 
fluid sample collected off each of the 20 patients was that 
amylase was detected in each and every one of the infected 
fluid samples . Many of the plasma samples showed unde 
tectably low concentrations of amylase . 
[ 0119 ] The results of FIG . 2 suggest a marked difference 
in the amylase activity between plasma samples , where 
infection is absent , and infection sites , where infection was 
present . 
10120 ) FIG . 3A shows the outcome when Wilcoxon 
matched pairs signed rank testing is applied to the results . A 
separate between the two sample group types is establish 
with P = 0 . 002 . FIG . 3B shows the amylase activity compari 
son between wound sourced control samples and blood 
sourced control samples ( p = 0 . 3846 ) . FIG . 3C shows the 
amylase activity comparison between patients providing 
infected samples and patients providing non - infected 
samples ( p < 0 . 0001 , n = 20 ) . In FIGS . 2 , 3A , 3B and 3C an 
activity difference is under consideration . 
[ 0121 ] FIG . 4 shows the results from Western blot analysis 
of amylase size ( kDa ) distribution from a variety of samples 
and is indicative of cleavage / degradation of the amylase 
occurring . 
[ 0122 ] FIG . 5 considers the concentration difference for 
pairs of results , one of the pair being a plasma sample and 
the other being an infected site sample taken from the same 
patient . 20 sample pairs were considered in this case con 
sistent with the patients in the library of FIG . 1 . FIG . 5 
shows that the difference in concentration between the two 
samples from the same patient is significant in each and 
every case tested ; 100 % increase in concentration in the 
infected sample in many cases . The sensor showed excellent 
sensitivity ( 98 % ) and high specificity ( 90 % ) with respect to 
infection in the measurement results generated . Sensitivity 
being the ability to correctly identify those with the infection 
( true positive rate ) ; specificity being the ability to test 
correctly to identify those without the infection ( true nega 
tive rate ) . 
[ 0123 ] In FIG . 6 the outcome from the application of 
Mann Whitney matched - pairs signed rank testing is seen . 
The separation between the two sample types is clearly 
established with P < 0 . 0001 . 
[ 0124 ] FIGS . 7a , 76 and 7c show the outcome from the 
application of Mann Whitney matched pair signed rank 
testing . With FIG . 7a being infected cases , FIG . 7b being 
non - infected cases and FIG . 7c controls . 
[ 0125 ] The results show that the difference in amylase 
between a site of interest and intravascular fluid ( defined 
above ) can be used to determine the presence of infection , 
or its likelihood , at the site of interest . If the activity 
difference ( site of interest versus intravascular fluid ) is 
considered , the distinction is statistically significant . If the 
concentration is considered , then the distinction is highly 
statistically significant . The amylase difference between 
infected and non - infected sites is highly sensitive to the 
presence of infection . 
( 0126 ] The experimental results show that the detection of 
activity and more usefully concentration difference reveals 
whether or not infection is present at the site . This informa 
tion could be used to direct subsequent and further investi 
gations . For instance , a determination as to the nature of the 
infection could be sought , for instance by microbial culture , 
microscopy , biochemical testing , molecular testing , immu 
noglobulin binding to amylase or others . This information 
on the infection can be combined with information on the 
incident or procedure leading to the wound and then used by 
a medical practitioner to diagnose a medical condition and 
the form of treatment appropriate . 
10127 ] A significant benefit of being able to establish that 
infection is present at the wound site and needs treatment is 
that no treatment need be given where no infection is 
established to be present . At the moment , clinical practice 
errs on the side of caution and so antibiotics , as infection 
treatment , are administered in most situations . This repre 
sents unnecessary antibiotic use and so contributes to wasted 
costs and , more significantly , increased build - up of resis 
tance to antibiotics . 
0128 ] . The applicant has established that this new pattern 
of amylase distribution is valid and applicable for detecting 
infection at sites . 
10129 ] . In terms of the mechanism by which amylase 
distribution arises at the site of infection , then there are 
various possibilities . Amylase which is occurring naturally 
in the body and distributed throughout the body could be 
caused to collect at the infection site . 
[ 0130 ] One way this could be caused to happen is through 
enhanced vascular permeability , and reduced lymphatic 
clearance : ( the so - called enhanced permeability and reten 
tion effect ) . Histamine release has been reported to stimulate 
amylase secretion and increase vascular permeability , 
thereby augmenting the EPR effect . 
[ 0131 ] However , the significant , selective and specific 
sequestration of amylase to a focus of infection reported 
herein is to a greater extent than seems explained by the EPR 
effect . 
[ 0132 ] Potentially , the effect is suggested to be due to 
invasive infection being accompanied by constant bradyki 
nin production which amplifies the limited enhanced vas 
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provides an in vitro diagnostic device . The invention pro 
vides in vitro testing for the marker . 
Other Applications of the Detection 
10141 ] It has been suggested that pharmaceutical com 
pounds can be introduced to a body in an inactive form , with 
the inactive form arising because the pharmaceutical com 
pound is linked in some way to another compound which 
inactivates it . Whilst the inactive form would be adminis 
tered to the body as a whole , for instance through injection , 
it could be activated at the site of interest by the activity of 
the amylase at that site . Thus the inactive form could be 
designed such that amylase causes it to breakdown or 
amylase catalyses the breakdown such that the active com 
pound is rendered pharmaceutically active . The analysis of 
the invention could be used to establish that there is suffi 
cient amylase , by activity and / or concentration , at the site to 
cause the activation and / or to impact upon the dosage given 
or delivery method used because of the level of amylase 
present at the desired release location . 
10142 ] In a similar manner , the transportation of the phar 
maceutical compound as part of a combination with amylase 
( described further in the next section ) , could be inspected by 
the analysis of the present invention to detect for the amylase 
following breakdown and hence the release of the active 
compound . Verification of the release would be provided . 
Using Amylase as a Transportation Mechanism 
Pharmaceutical Compounds 
for 
cular permeability observed in non - specific infection , such 
as that produced in a surgical insult . 
[ 0133 ] The applicant ' s view is that the most plausible 
mechanism is that once in this pharmacokinetic compart 
ment that amylase complexes immunoglobins , resulting in 
entrapment . The applicant references this as Microbe - Asso 
ciated Large Molecule Trapping and Aggregation phenom 
enon , MALTA phenomenon . 
[ 0134 ] Finally , certain classes of micro - organisms secrete 
amylase themselves , for example C . perfringens ( a cause of 
gas gangrene ) , C . tetanii ( tetanus ) , C . difficile ( hospital 
acquired pseudomembranous colitis ) and B . cereus ( food 
poisoning ) are all within the Bacillus and Clostridium genus 
and those are known to be capable of prolific amylase 
secretion and so may cause the observed increased amylase 
levels around infected sites , potentially several orders of 
magnitude higher . 
[ 0135 ] The mechanism by which the amylase sequesters to 
the infection site is not material to the invention . The 
invention has demonstrated that this effect is medically 
indicative of infection and makes use of it , irrespective of 
the mechanism of sequestration , to produce clinically useful 
results . 
101361 . Initial results show that the use of amylase as a 
biomarker of infection at sites is a robust method and is 
capable of dealing with the likely variations in pH , calcium 
and proteolytic activity to be expected at such sites . The use 
of amylase as a biomarker of infection also seems capable of 
successful operation in the context of a wide variety of 
different dressings , including Negative Pressure Wound 
Therapy , antibiotic treatment , site and anatomical plane , 
together with severity of infection . 
[ 0137 ] The description above makes it clear that the 
method and the sensors used are capable of detecting 
infection at a site . As an extension of that , it is possible to 
link the concentration level of amylase observed to the level 
of infection ; higher levels of infection generating higher 
concentrations of amylase at the site and in the samples . 
[ 0138 ] In a further extension of that method , it is possible 
to establish the form of the infection which is present . One 
possibility in this respect is that the body will generate 
antibodies specific to the infection caused by the specific 
bacteria which is the cause of the infection . These antibodies 
have been observed to form complexes of immunoglobulins 
and amylase . This means that the antibodies specific to the 
infection will be in the sample taken and so could be 
identified in parallel with the detection of the amylase 
concentration . 
[ 0139 ] Amylase has been observed to have the capacity to 
complex with immunoglobulins . This means that the anti 
bodies specific to the infection will be in the sample taken 
and so could be identified in parallel with the detection of 
amylase . In one such embodiment , this could be done via 
multiplex sensing . 
[ 0140 ] The interaction between the at least a part of the 
sample and the sensor occurs without the need for the human 
or animal body from which the sample arises being present 
and / or without any interaction between the device and the 
human or animal body which is the source of the sample . 
The method is provided outside the normal biological con 
text of the sample . The method is performed outside of the 
human or animal body and distant therefrom . The method is 
provided in - vitro by the device and the sensor . The invention 
[ 0143 ] Whilst it has been suggested that amylase which is 
already naturally occurring at a site could be used to turn an 
inactive form including a pharmaceutical compound into an 
active form , potentially by releasing the pharmaceutical 
compound , the applicant has realised that amylase itself 
could be used as a transportation mechanism . 
[ 0144 ] When a site transitions from a non - infected to an 
infected site , amylase moves to and accumulates at the site , 
as established by the applicant above . If that amylase or 
some portion of it was linked to a pharmaceutical com 
pound , then the pharmaceutical compound would be pref 
erentially transported to the infection site . The same could 
apply to other sites at which amylase accumulates or is 
drawn in other disease situations . Thus amylase offers a 
targeted delivery system in such cases . 
[ 0145 ] Once at the site , release of the pharmaceutical 
compound would be triggered . 
[ 0146 ] A variety of constructs could be used . The amylase 
could be linked directly to the pharmaceutical compound . 
The amylase could be linked to an intermediary which is in 
turn linked to the pharmaceutical compound . 
[ 0147 ] The linking could be provided using a number of 
bio - conjugate techniques and chemistries , including but not 
limited to zero - length cross - linkers homo - bifunctional or 
heterobifunctional spacers which can be non - biodegradable 
( such as polyethylglycol ) or biodegradable ; homogenous or 
heterogenous . 
10148 ] The pharmaceutical compound could be an antibi 
otic , for instance for treating infection at the site where the 
amylase accumulates . Other pharmaceuticals could be anal 
gesics , growth factors etc . 
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Sensor 
[ 0149 ] The sensor employed in the sample testing 
described above can be generally categorised as a graphene 
label free immunosensor . In more detail it is a highly 
sensitive a - amylase immunosensor platform , produced via 
in situ electropolymerization of aniline onto a graphene 
support . Electropolymerization has a material role in 
improving the sensitivity in detection for amylase and 
providing lower limits of quantification . This is a significant 
difference when compared with the assembly of other sen 
sors developed for other purposes , such as those disclosed in 
WO2015 / 001286 . At the same time , excellent reproducibil 
ity and stability in detection are provided , as shown in FIGS . 
8 , 9 , 10 and 11 . Covalently binding an a - amylase specific 
antibody to a polyaniline ( PANI ) layer and controlling 
device assembly using electrochemical impedance spectros 
copy ( EIS ) provides a highly linear response against a - amy 
lase concentration . 
[ 0150 ] To improve reproducibility of absolute readings 
using the sensor , when such a graphene sensor is applied , the 
invention suggests the use of a double sensor where simul 
taneous or near simultaneous readings are taken , for instance 
with respect to the plasma versus fluid of interest . This 
results in a relative scale of the magnitude of the difference , 
and hence a solution for the problem . 
[ 0151 ] Further detail on the testing of the sensor for this 
purpose and further detailed information on the construction 
of the sensor is provided below . 
10152 ] The type of sensor used in the testing of the 
invention is beneficial when compared with most existing 
devices . In most cases , such devices are far from being 
bedside monitoring devices for a - amylase detection . Cur 
rent a - amylase assays in clinical use are laboratory based , 
utilize analytical equipment with a large footprint , have an 
appreciable turnaround time ( TAT ) , measure activity rather 
than concentration , and are susceptible to hemolysis and 
inactivation . These substantial limitations restrict further 
expansion of a - amylase based diagnostics and theranostics 
into viable clinical practice . No use of the detection of 
amylase and particularly a - amylase to indicate infection has 
been made before . 
responding to the carrier transfer from the modified elec 
trode to the ferricyanide in the solution . Thus , the observed 
diameter increase is explained as the adsorption of plasma 
onto anti - alpha amylase following an antigen - antibody reac 
tion , where the adsorption of plasma effectively blocks the 
[ Fe ( CN ) 6 ] 3 - 14 - leading to an increase of Rct . The Rct in the 
Nyquist plot increased linearly with the amylase concentra 
tions . This is as expected because protein structures bound 
to the surface of an electrode typically act as barriers to 
electric transfer . The average slope of the Rct versus log 
[ amylase , U / L ] was 0 . 348 K22 / [ amylase , U / L ] with an R ? 
coefficient of determination of 0 . 93 . The limit of detection 
( LOD ) was 0 . 0025 U / L . This was as expected as protein 
structures bound to the surface of an electrode typically act 
as barriers to electric transfer . 
[ 0157 ] Mouse Plasma 
[ 0158 ] In order to demonstrate that the sensor function 
was effective when exposed to a more complex biological 
fluid , mouse plasma containing known quantities of amylase 
were used . a - amylase concentrations were measured in 
un - spiked and plasma samples with purified human - a - amy 
lase . The linear response ranged from 1 to 1000 U / L and the 
average slope was of 0 . 472 K2 [ amylase , U / L ] . The EIS 
calibration curve of the immunosensor in response to 
increasing concentrations of amylase in mouse plasma 
showed no adverse effect on sensor performance in the 
presence of a more complex fluid compared to the PBS 
( FIG . 9 ) . 
[ 0159 ] Human Plasma 
[ 0160 ] To provide proof of function for a clinically useful 
device , human plasma samples obtained from a patient 
suffering with clinical infection were analyzed . By spiking 
the human plasma with known concentrations of amylase we 
were able to determine the effectiveness and LOD of the 
sensor at physiologically relevant analyte concentrations . 
[ 0161 ] Nyquist plots ( FIG . 10 ) of EIS spectra show the 
dynamic range detectable when the sensor was exposed to 
various human plasma concentrations ( 9 . 9 - 1009 . 9 U / L ) . 
[ 0162 ] Overall , the sensor was demonstrated to offer 
highly sensitive detection and a remarkably wide limit of 
quantification ( 0 . 025 - 1000 IU / L ) compared to a - amylase 
assays in current clinical use . 
[ 0163 ] In addition , the sensor had a maximum interval to 
obtain a result of 300 seconds . This compares very well with 
existing devices in clinical practice , where , despite turn 
around times ( TAT ) being a key indicator of laboratory 
performance , the current TAT for clinical assays is around 45 
minutes . 
[ 0164 ] Moreover haemolysis , sample inactivation , and the 
presence of contaminants interfering with colorimetric 
assays commonly lead to assay failure with current clinical 
assay systems . Since the system described in this document 
is label - free , and does not require either colorimetric change , 
it is reasonable to support the notion that the new technology 
will not be affected such factors . 
101651 . Finally , it is worth noting that the results indicate a 
three - log fold expansion in the lower limit of quantification 
when compared to current clinical assay systems . This is of 
interest to forensic medicine where detection of amylase can 
lead to a DNA profile from saliva , semen or vaginal secre 
tions . 
Demonstrations of Sensor Performance 
[ 0153 ] The performance of the sensor was explored in 
various ways , including : determination of amylase in a 
blood plasma mimic ; determination of amylase in mouse 
plasma ; and determination of amylase in human plasma . 
[ 0154 ] Blood Plasma Mimic 
[ 0155 ] The sensor was tested for its ability to measure 
amylase concentrations in a phosphate buffered solution that 
was used as a blood plasma mimic . Increasing amylase 
concentrations , from 1 to 500 U / L , which covers the clini 
cally relevant range of amylase levels in the human body , 
were applied to individual sensors . Both Nyquist plots ( FIG . 
8A ) and the resulting EIS calibration curve ( FIG . 8B ) clearly 
demonstrate the effective response of the immunosensor to 
increasing amylase concentrations . 
[ 0156 ] The diameter of the semicircle increased with 
increasing amylase concentrations demonstrating an 
increased resistance as a result of increased analyte concen - 
tration at the sensor surface . In general , the change in the 
semicircle diameter is a result of the change in the interfacial 
charge transfer resistance ( Ret ) ; that is , the resistance cor 
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Sensor Construction 
[ 0166 ] Electrochemical impedance spectroscopy ( EIS ) 
enables detection and signal output due to its ability to 
measure subtle changes in the electrochemical properties of 
materials at their interface with conducting electrodes . Gold , 
zinc oxide , iron oxide , and carbon are the main substrates 
that are being developed for use in such sensors , but carbon 
nanostructures , and graphene , are alternatives to gold as 
electrode substrates . 
[ 0167 ] Graphene is of particular interest as a biosensor 
platform due to intrinsic properties such as its large surface 
area , high electrical conductivity and biocompatibility . Gra 
phene based devices have been developed that can measure 
minute changes in analyte concentration levels . Composed 
of sp2 carbon , graphene is chemically unsaturated . Intrinsi 
cally , it can undergo covalent addition to change the carbons 
from sp² to spa following hybridization , however , carbon 
atoms in the graphene basal plane are protected by their 
IT - conjugation system , the motion of which is constrained by 
surrounding carbon atoms . Therefore , basal plane covalent 
addition usually encounters large energy barriers , and reac 
tive chemical groups , such as atomic hydrogen , fluorine , and 
pre - cursors of other chemical radicals , are usually needed as 
reactants . The controlled functional association of biomol 
ecules with graphene is therefore key to developing any high 
throughput biosensor platform . 
[ 0168 ] FIG . 12 provides a schematic illustration of the 
construction sequence for a suitable sensor . 
[ 0169 ] Polyaniline ( PANI ) is a conductive polymer and is 
used as an additive transducer layer in the sensor to avoid the 
introduction of graphene surface defects . In addition the use 
of PANI improves antibody attachment to sensor electrodes 
while preserving optimal electrical characteristics . In addi 
tion , PANI has excellent acid / base sensitivity , a huge range 
of tunable conductivity , redox sensitivity , environmental 
stability , short reversible response times , and is easily syn 
thesized and functionalized . 
[ 0170 ] The sensor of this document is an a - amylase 
specific immunosensor , using a combination of electro 
polymerization of PANI on a graphene support and subse 
quent antibody binding to the polymer film . 
[ 0171 ] The selection of electropolymerization has a mate 
rial role in improving the sensitivity in detection for amylase 
and providing lower limits of quantification . At the same 
time , excellent reproducibility and stability in detection are 
provided , as shown in FIGS . 8 , 9 , 10 and 11 . 
[ 0172 ] The biosensor platform enables fully quantitative 
analysis of analyte concentrations in a simulated biological 
sample and in human plasma . The device displays a linear 
response to increasing a - amylase concentration between 1 
and 1000 International Units / L ( IU / L ) , and a LOD of 0 . 025 
U / L . This increased sensitivity arises because of electro 
chemical deposition . 
[ 0173 ] In construction , a screen - printed graphene elec 
trode was functionalized via polymerization with a thin film 
of polyaniline to provide amine groups on the graphene / 
PANI . The PANI film was formed by coating the electrode 
in a solution of aniline and subsequent electropolymeriza 
tion to form a conductive polymer layer over the graphene 
support , enabling the transport of electron carriers to the 
graphene . 
[ 0174 ] Having deposited polyaniline , the sensor was then 
functionalized through covalently linking a a - amylase anti 
body to the PANI layer . A carbodiimide crosslinker chem 
istry EDAC / NHS was used for the specific activation of the 
- COOH terminated amino acid chains in the antibody . This 
forms a highly reactive O - Acylisourea intermediate that 
rapidly reacts with NHS to produce a stable succinimydyl 
ester . This ester then undergoes a nucleophilic substitution 
reaction with the amine groups on the PANI , leading to the 
formation of an orientated antibody grafted PANI layer . Due 
to exposure to the EDAC / NHS reagents , it is possible that 
each of — COOH groups at the antibody may have been 
activated . It is not possible therefore to ensure exclusive 
antibody binding through the F region , only that orientation 
via the F , region is significantly higher than with random 
antibody adsorption . Bovine serum albumin ( BSA ) was then 
added to the sensor surface randomly , and serves to prevent 
any non - specific interactions with the sensor surface thereby 
eliminating the possibility of the sensor generating any 
non - specific background signal . 
0175 ] Whilst the above is an example of a suitable sensor , 
other suitable sensors capable of detecting amylase activity 
and more preferably concentration , can be used . These 
include the sensors disclosed in : 
[ 0176 ] Federal Drug Agency ( FDA ) 510 ( k ) substantial 
equivalence determination decision summary device only 
template . http : / / www . accessdata . fda . gov / cdrh docs / re 
views / K040534 . pdf ; ( b ) Bowling , J . L . ; 
[ 0177 ] Katayev , A . , An evaluation of the Roche Cobas c 
111 . Lab Medicine 2010 , 41 ( 7 ) , 398 - 402 . 
Together with the sensors described in the following table 
and which are available in clincial practice . 
AMP = Amperometric , EIS = Electrochemical Impedance 
Spectroscopy , FAU = Fungal Amylase Unit , FIA = Flow Injec 
tion Analysis , KNU = kilo Novo unit , LOD = Limit of Detec 
tion , LR = Linear Range , nkat = nanokatals 
Detection 
Assay Design Sequential Process Technique Limits of detection Specificity Ref . 
AMP [ 145 ] Rate of 
product 
formation 
LOD : 2 nkat / mL Any a - 
( 0 . 117 . 64 units / mL ) amylase 
when reaction time 
5 min 
Flow system using a 
peroxide electrode and 
enzyme membrane with 
glucose oxidase , a 
glucosidase and 
optionally mutarotase 
cross - linked by gelatin 
glutaraldehyde 
Q - glucosidase 
converts maltose to 
C - D - glucose . 
Mutarotase 
converts a - D 
glucose to B - D 
glucose which is 
determined via 
glucose oxidase 
0 . 5 nkat / mL 
( 0 . 02941 units / mL ) 
when reaction time 
30 min 
LR : 0 . 1 - 3 mmol / L 




Assay Design Sequential Process Technique Limits of detection Specificity Ref . 
LOD : 5 units / mL Any a - 
LR : 5 - 250 units / mL amylase 
[ 146 ] 
LOD : 
LR : 0 - 30 units / mL 
Any a - 
amylase 
[ 147 ] 
[ 148 ] LOD : 0 . 0048 FAU Any a - 
LR : 0 . 005 - 0 . 06 FAU amylase 
LOD : 20 U / L 
LR : 2 . 2 - 27 . 8 mM 
Anya 
amylase 
LR : 0 - 190 KU / L Any a - 
amylase 
[ 147 ] 
Screen - printed a - glucosidase AMP 
electrodes with converts maltose to 
immobilized a a - D - glucose . 
glucosidase , glucose Mutarotase 
oxidase and mutarotase converts a - D 
modified with Prussian glucose to B - D 
Blue glucose which is 
determined via 
glucose oxidase 
Flow - injection device a - glucosidase AMP 
using maltopentaose as converts maltose to 
substrate . a - glucosidase 5 - d - glucose . 
immobilised on pre Glucose oxidase 
activated membrane . coverts 5 - d - glucose 
Glucose oxidase to gluconic acid and 
immobilized on hydrogen peroxide 
electrode which is measured 
Spectrophotometric flow Amylose incubated SIA / FIA 
injection measuring with sample to 
brick red complex produce maltose . 
formation at 540 nm 3 , 5 dinitrosalicylic 
acid and maltose 
boiled 
Use of portable personal Sample , a 
glucose meter glucosidase and 
maltopentaose 
incubated 15 min at 
37° C . 
Flat - chip micro analytical Maltose Electro - 
sensor used as part of a phosphorylase chemical 
Micro - Electro phosphorylates and 
Mechanical Systems . maltose . Glucose Lateral 
Pre - column and flat oxidase converts flow 
enzyme electrode phosphorylated 
incorporated into a flow maltose to gluconic 
cell where maltose acid and hydrogen 
phosphorylase , glucose peroxide which is 
oxidase and peroxidase measured 
immobilised 
Colorimetric assay Disposable test AMP 
biosensor system using strip placed under 
Gal - G2 - CNP , tongue ( 25 ul ) 
chromogenic substrate Once strip inserted 
for a - amylase . CNP is a into reader and 
yellow product once saliva moved onto 
hydrolysed which can be the reagent paper . 
measured The entire test 
photometrically at takes roughly 30 
430 nm . sec . 
Flow injection Sample degradation FIA 
spectrophotometric of complexes 
analysis based on starch - measured in flow 
iodine complexes channel 
Immobilized layer of Sample placed on 
starch gel on thick - film starch gel 
magneto elastic sensor 
and presence of a 
amylase alters the 
resonance frequency 
Spectrofluorimetric Sample incubated FIA 
using the quenching of with starch in flow 
luminescence intensity channels 
( 634 nm ) of nano CdS 
doped in sol - gel of 
different concentrations 
of maltose 
Glycogen / amylopectin Sample incubated EIS 
spin - coated on gold with film 
coated quartz crystals 
( case frequency of 10 
MHz ) . Films cross - linked 
with hexamethylene 
LR : 10 - 230 U / mL Any a - 
amylase [ 150 ] 
[ 151 ] Rate of 
starch 
digestion 
LOD : 60 NU / mL 
LR : 0 . 25 - 5 . 0 
KNU / mL 
Any a - 
amylase metric 
LR : 75 - 125 U / mL Anya - 
amylase 
[ 152 ] 
[ 153 ] LOD : 5 . 7 x 10 - 11 
mol / L 
LR : 4 . 8 x 10 - 10 - 
1 . 2 x 10 - 5 mol / L 
Anya - 
amylase 
Any a - 
amylase 
[ 154 ] 
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Detection 
Assay Design Sequential Process Technique Limits of detection Specificity Ref . 
LOD : 1 . 944 mU 
LR : 0 - 0 . 54 U 
Any a 
amylase 
LOD : Any al 
LR : 0 . 66 - 9 . 83 U / mL amylase 
diisocyanate . Film 
degradation measured 
with quartz crystal 
microbalance 
Degradation of starch - Sample incubated 
triiodide measured using with starch 
platinum redox sensor triiodide 
for direct potentiometric 
determination 
Glucose oxidase - based 
biosensor measuring the 
decrease in dissolved 
oxygen concentration 
related to starch 
concentration . 
Glutaraldehyde as a 
cross - linker 
Layer of salivary The electroactive 
antibody on Au was oxidized or 
electrode and reduced depending 
interactions monitored on concentration of 
by an electroactive salivary a - amylase 
indicator ( K3Fe ( CN ) 6 ) . present 
AMP [ 113 Antibody to 
antigen 
LOD : 1 . 57 pg / mL 
LR : 0 . 003 - 0 . 016 




1 . A method of indicating the presence of a bacterial 
infection in a biological sample by investigating an enzyme 
for bacterial infection , the method comprising : 
a . providing a device , the device including a biosensor , an 
interaction arising between the biosensor and the 
enzyme when the enzyme is present in the biological 
sample ; 
b . contacting at least a part of the biological sample with 
the biosensor of the device ; 
c . analysing the at least a part of the biological sample 
with respect to the enzyme by detecting for the inter 
action between the biosensor and the enzyme ; 
d . indicating a characteristic of the enzyme using the 
device , the characteristic being the presence or absence 
of the enzyme ; 
e . wherein the enzyme is a - amylase . 
2 . ( canceled ) 
3 . The method according to claim 1 , wherein the method 
is a method of diagnosing infection . 
4 . The method according to claim 1 , wherein the method 
is a method of analysing for a - amylase levels at a site 
compared with a - amylase levels at another location of the 
same patient , such as the blood . 
5 . ( canceled ) 
6 . The method according to claim 1 , wherein the method 
is a method of quantifying the amount of a - amylase in the 
at least a part of the biological sample . 
7 . The method according to claim 1 , wherein the method 
is a method of quantifying the concentration of a - amylase 
and / or the activity of a - amylase relative to the concentration 
and / or activity of a - amylase in a reference sample . 
8 . The method according to claim 7 , wherein the reference 
sample is another biological sample taken from the same 
source . 
9 . The method according to claim 7 , wherein the reference 
sample is taken from another site on the source to the site 
being analysed . 
10 . The method according to claim 4 , wherein the site is 
one or more of : on the exterior of a body ; the interior to a 
body ; a surgical site ; a disease site ; a pathology site ; an 
infection site ; an injury site ; and a burn site . 
11 . ( canceled ) 
12 . The method according to claim 1 , wherein the device 
includes the biosensor together with one or more or all of : 
a power source ; control electronics ; a computer processor ; 
computer memory ; a user interface ; a user viewable display ; 
a signal output connection , and a signal input connection . 
13 . The method according to claim 1 , wherein the bio 
sensor is : screen printed on to a part of the device ; and / or is 
a graphene based sensor ; and / or includes an amylase anti 
body and / or includes electropolymerization of a component 
of the biosensor . 
14 . The method according to claim 13 , wherein the 
biosensor includes an a - amylase specific antibody . 
15 . The method according to claim 1 , wherein the bio 
sensor comprises an electrochemical impedance spectros 
copy sensor . 
16 . The method according to claim 1 , wherein the bio 
sensor has a linear response against a - amylase concentra 
tion and / or detects concentrations of a - amylase as low as 
100 International Units / L ( IU / L ) . 
17 . The method according to claim 1 , wherein the bio 
sensor detects concentrations of a - amylase as low as 1 
International Units / L ( IU / L ) . 
18 . The method according to claim 1 , wherein the bio 
sensor has a limit of detection as low as 0 . 025 U / L . 
19 . ( canceled ) 
20 . The method according to claim 1 , wherein the char 
acteristic is one or more of : the presence of infection due to 
the presence of a - amylase ; the absence of infection due to 
the absence of a - amylase ; the presence of infection due to 
the level of a - amylase ; the absence of infection due to the 
level of a - amylase ; the presence of infection due to the 
quantity of a - amylase ; the absence of infection due to the 
quantity of a - amylase ; the presence of infection due to the 
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activity of a - amylase ; the absence of infection due to the 
quantity of a - amylase ; the presence of infection due to the 
concentration of a - amylase ; and the absence of infection 
due to the concentration of a - amylase . 
